Petra Marusic

Petra Marusic

Auto-generated profile, based on publicly available information

Petra Marusic

Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in The Lancet
Verified
Journal Article
Closed access
MHMichael S. Hofman
Michael S. Hofman
NLNathan Lawrentschuk
Nathan Lawrentschuk
RFRoslyn J Francis
Roslyn J Francis
CTColin Tang
Colin Tang
IVIan Vela
Ian Vela
DMDeclan G Murphy
Declan G Murphy

1 February 2013 in Hypertension
Verified
Journal Article
Closed access
DHDagmara Hering
Dagmara Hering
ELElisabeth Lambert
Elisabeth Lambert
PMPetra Marusic
Petra Marusic
AWAntony S. Walton
Antony S. Walton
HKHenry Krum
Henry Krum
MSMarkus P SCHLAICH
Markus P SCHLAICH
Renal denervation (RDN) has been shown to reduce blood pressure (BP) and muscle sympathetic nerve activity (MSNA) in patients with resistant hypertension. The mechanisms underlying sympathetic neural inhibition are unknown. We examined whether RDN differentially influences the sympathetic discharge pattern of vasoconstrictor neurons in patients with resistant hypertension. Standardized office BP, single-unit MSNA, and multi-unit MSNA were obtained at baseline and at 3-month follow-up in 35 patients with resistant hypertension. Twenty-five patients underwent RDN, and 10 patients underwent repeated measurements without RDN (non-RDN). Baseline BP averaged 164/93 mm Hg (RDN) and 164/87 mm Hg (non-RDN) despite use of an average of 4.8±0.4 and 4.4±0.5 antihypertensive drugs, respectively. Mean office BP decreased significantly by −13/−6 mm Hg for systolic BP ( P <0.001) and diastolic BP ( P <0.05) with RDN but not in non-RDN at 3-month follow-up. RDN moderately decreased multi-unit MSNA (79±3 versus 73±4 bursts/100 heartbeats; P <0.05), whereas all properties of single-unit MSNA including firing rates of individual vasoconstrictor fibers (43±5 versus 27±3 spikes/100 heartbeats; P <0.01), firing probability (30±2 versus 22±2% per heartbeat; P <0.02), and multiple firing incidence of single units within a cardiac cycle (8±1 versus 4±1% per heartbeat; P <0.05) were substantially reduced at follow-up. BP, single-unit MSNA, and multi-unit MSNA remained unaltered in the non-RDN cohort at follow-up. RDN results in the substantial and rapid reduction in firing properties of single sympathetic vasoconstrictor fibers, this being more pronounced than multi-unit MSNA inhibition. Whether the earlier changes in single-unit firing patterns may predict long-term BP response to RDN warrants further exploration.

1 July 2014 in Hypertension
Verified
Journal Article
Closed access
DHDagmara Hering
Dagmara Hering
PMPetra Marusic
Petra Marusic
AWAntony S. Walton
Antony S. Walton
ELElisabeth Lambert
Elisabeth Lambert
HKHenry Krum
Henry Krum
MSMarkus P SCHLAICH
Markus P SCHLAICH
Renal denervation (RDN) reduces muscle sympathetic nerve activity (MSNA) and blood pressure (BP) in resistant hypertension. Although a persistent BP-lowering effect has been demonstrated, the long-term effect on MSNA remains elusive. We investigated whether RDN influences MSNA over time. Office BP and MSNA were obtained at baseline, 3, 6, and 12 months after RDN in 35 patients with resistant hypertension. Office BP averaged 166±22/88±19 mm Hg, despite the use of an average of 4.8±2.1 antihypertensive drugs. Baseline MSNA was 51±11 bursts/min ≈2- to 3-fold higher than the level observed in healthy controls. Mean office systolic and diastolic BP significantly decreased by –12.6±18.3/–6.5±9.2, –16.1±25.6/–8.6±12.9, and –21.2±29.1/–11.1±12.9 mm Hg ( P <0.001 for both systolic BP and diastolic BP) with RDN at 3-, 6-, and 12-month follow-up, respectively. MSNA was reduced by –8±12, –6±12, and –6±11 bursts/min ( P <0.01) at 3-, 6-, and 12-month follow-up. The reduction in MSNA was maintained, despite a progressive fall in BP over time. No such changes were observed in 7 control subjects at 6-month follow-up. These findings confirm previous reports on the favorable effects of RDN on elevated BP and demonstrate sustained reduction of central sympathetic outflow ≤1-year follow-up in patients with resistant hypertension and high baseline MSNA. These observations are compatible with the hypothesis of a substantial contribution of afferent renal nerve signaling to increased BP in resistant hypertension and argue against a relevant reinnervation at 1 year after procedure.

1 October 2013 in International Journal of Cardiology
Verified
Journal Article
Closed access
MSMarkus P SCHLAICH
Markus P SCHLAICH
BBBradley Bart
Bradley Bart
DHDagmara Hering
Dagmara Hering
AWAnthony Walton
Anthony Walton
PMPetra Marusic
Petra Marusic
MEMurray D. Esler
Murray D. Esler

1 April 2017 in International Journal of Cardiology
Verified
Journal Article
Closed access
DHDagmara Hering
Dagmara Hering
PMPetra Marusic
Petra Marusic
JDJacqueline Duval
Jacqueline Duval
YSYusuke Sata
Yusuke Sata
GHGeoffrey Head
Geoffrey Head
MSMarkus P SCHLAICH
Markus P SCHLAICH

1 February 2017 in Hypertension
Verified
Journal Article
Closed access
MZMaria T.K. Zaldivia
Maria T.K. Zaldivia
JRJennifer Rivera
Jennifer Rivera
DHDagmara Hering
Dagmara Hering
PMPetra Marusic
Petra Marusic
YSYusuke Sata
Yusuke Sata
KPKarlheinz Peter
Karlheinz Peter
Overactivation of renal sympathetic nervous system and low-grade systemic inflammation are common features of hypertension. Renal denervation (RDN) reduces sympathetic activity in patients with resistant hypertension. However, its effect on systemic inflammation has not been examined. We prospectively investigated the effect of RDN on monocyte activation and inflammation in patients with uncontrolled hypertension scheduled for RDN. Ambulatory blood pressure, monocyte, and monocyte subset activation and inflammatory markers were assessed at baseline, 3 months, and 6 months after procedure in 42 patients. RDN significantly lowered blood pressure at 3 months (150.5±11.2/81.0±11.2 mm Hg to 144.7±11.8/77.9±11.0 mm Hg), which was sustained at 6 months (144.7±13.8/78.6±11.0 mm Hg). Activation status of monocytes significantly decreased at 3 months ( P <0.01) and 6 months ( P <0.01) after the procedure. In particular, classical monocyte activation was reduced at 6 months ( P <0.05). Similarly, we observed a reduction of several inflammatory markers, including monocyte–platelet aggregates (3 months, P <0.01), plasma monocyte chemoattractant protein-1 levels (3 months, P <0.0001; 6 months, P <0.05), interleukin-1β (3 months, P <0.05; 6 months, P <0.05), tumor necrosis factor-α (3 months, P <0.01; 6 months, P <0.05), and interleukin-12 (3 months, P <0.01; 6 months, P <0.05). A positive correlation was observed between muscle sympathetic nerve activity and monocyte activation before and after the procedure. These results indicate that inhibition of sympathetic activity via RDN is associated with a reduction of monocyte activation and other inflammatory markers in hypertensive patients. These findings point to a direct interaction between the inflammatory and sympathetic nervous system, which is of central relevance for the understanding of beneficial cardiovascular effects of RDN.